DURHAM –  IQVIA Holdings Inc. (IQV) on Wednesday reported third-quarter profit of $283 million, part of a full quarterly financial report card that dew praise from its top executive.

“IQVIA had another outstanding quarter of operational and financial performance,” said Ari Bousbib, chairman and CEO of IQVIA, in a statement.

“Each of our business segments delivered impressive organic revenue growth at constant currency, we increased adjusted diluted earnings per share by over 14 percent, and free cash flow generation was very strong. Despite the global macro environment, demand for IQVIA services and offerings continues to be strong across both the commercial and the clinical portfolios, with R&DS delivering over $2 billion of services bookings for the first time ever.”

The Durham-based company said it had profit of $1.49 per share. Earnings, adjusted for one-time gains and costs, came to $2.48 per share.

IQVIA delivers a ‘strong first quarter,’ tops Street expectations

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.39 per share.

The clinical testing company posted revenue of $3.56 billion in the period, also topping Street forecasts. Seven analysts surveyed by Zacks expected $3.55 billion.

For the current quarter ending in December, IQVIA expects its per-share earnings to range from $2.72 to $2.82.

The company said it expects revenue in the range of $3.65 billion to $3.75 billion for the fiscal fourth quarter.

IQVIA expects full-year earnings in the range of $10.10 to $10.20 per share, with revenue ranging from $14.33 billion to $14.43 billion.

Life science giant bringing hundreds of jobs to RTP for new lab hub